Penicillamine, a new oral therapy for Wilson's disease
JM Walshe - The American journal of medicine, 1956 - Elsevier
Of the compounds currently used in the treatment of Wilson's disease BAL appears to be the
most generally useful. However, it has a disadvantage in that toxic reactions eventually
develop in many patients. A new form of oral treatment with dimethyl cysteine (penicillamine)
is described. Given in doses varying from 0.5 to 1.5 gm. daily to six patients with Wilson's
disease, it provoked a very large increase in the urine excretion of copper; in five patients it
proved more active than BAL in this respect. No toxic reactions were observed in any patient …
most generally useful. However, it has a disadvantage in that toxic reactions eventually
develop in many patients. A new form of oral treatment with dimethyl cysteine (penicillamine)
is described. Given in doses varying from 0.5 to 1.5 gm. daily to six patients with Wilson's
disease, it provoked a very large increase in the urine excretion of copper; in five patients it
proved more active than BAL in this respect. No toxic reactions were observed in any patient …